Sign in Subscribe

crc-research

A collection of 723 issues

Cost analysis of risk-stratified screening based on FIT results

Skip to content The CRC Digest Cost analysis of risk-stratified screening based on FIT results Real-world data examined resource use and costs of a low-risk screening approach for people with previous negative fecal immunochemical tests. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice. Always

Practical guidance for integrating ctDNA testing into clinical care

Skip to content The CRC Digest Practical guidance for integrating ctDNA testing into clinical care A narrative review summarizes evidence for ctDNA minimal residual disease testing in gastrointestinal cancers, with strongest data supporting use in resected stage II colon cancer. (Clinical and Translational Oncology) This content is informational only and

KRAS G12D-targeted therapy tested in preclinical models

Skip to content The CRC Digest KRAS G12D-targeted therapy tested in preclinical models A nanomedicine delivering a KRAS G12D inhibitor showed promise in laboratory models of metastatic colorectal cancer. (Journal of Controlled Release) This content is informational only and does not constitute medical advice. Always consult your oncologist or care

RAS/BRAF wild-type patients: Maintenance strategies compared

Skip to content The CRC Digest RAS/BRAF wild-type patients: Maintenance strategies compared Three trials pooled data on left-sided, RAS/BRAF wild-type metastatic CRC to compare toxicity profiles of different maintenance approaches. (Journal of the National Cancer Institute) This content is informational only and does not constitute medical advice. Always

CRC Research Finding

Skip to content The CRC Digest ◇ Experimental nanomedicine targets KRAS G12D mutation in metastatic colorectal cancer Preclinical research describes a macrophage-hitchhiking delivery system combining gemcitabine and a KRAS G12D inhibitor that improved drug delivery to lung metastases and triggered immune responses in colorectal cancer models. (Journal of Controlled Release) This

CRC Research Update — May 24, 2026

Today's colorectal cancer research highlights

CRC Research Finding

Skip to content The CRC Digest ◆ Updated survival analysis for bevacizumab in metastatic CRC (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

CRC Research Update — May 23, 2026

Today's colorectal cancer research highlights

KRAS-G12C and PIK3CA hotspot mutations help reclassify MUTYH variants

Skip to content The CRC Digest KRAS-G12C and PIK3CA hotspot mutations help reclassify MUTYH variants Researchers found that the somatic mutations KRAS-G12C and PIK3CA-Q546K are highly enriched in MUTYH-associated polyposis tumors and rarely seen in sporadic cases, making them useful for reclassifying uncertain MUTYH variants. (Human Mutation) This content is

MSI-H and dMMR prevalence characterized in Hispanic/Latino colorectal cancer populations

Skip to content The CRC Digest MSI-H and dMMR prevalence characterized in Hispanic/Latino colorectal cancer populations A systematic review and meta-analysis evaluated the prevalence of microsatellite instability-high and mismatch repair deficiency biomarkers across 1,195 colorectal cancer samples from Hispanic/Latino individuals in Latin America. (International Journal of Colorectal